From intensifying therapy in ctDNA-positive bladder cancer to scaling it back in ctDNA-negative colon cancer, new data from ...

Equitable access to genomic testing for NSCLC patients is vital for advanced therapy access, with strategies including ...

Farber-co-led phase 3 trial shows that periodic ctDNA screening after surgery can help guide a decision to begin adjuvant ...

Circulating tumour DNA-guided adjuvant atezolizumab prolongs disease-free and overall survival in patients with ...

The Dana-Farber-co-led phase 3 IMvigor011 trial results show that periodic ctDNA screening after surgery can help guide a ...

Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...

Atezolizumab significantly enhances survival in ctDNA-positive muscle-invasive bladder cancer patients, addressing critical treatment gaps post-surgery.

Circulating tumor DNA (ctDNA) — genetic material shed from tumors into the bloodstream — may help risk-stratify patients with ...

A newer class of cancer drugs can delay disease progression or extend survival for breast cancer patients, multiple teams of ...